- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05854290
Comprehensive Cognitive and Affective Intervention for Mild Cognitive Impairment (MCI) for Foreign-Born Arab Americans (CoINTEGRATE)
A Pilot Randomized Controlled Trial of a Comprehensive Cognitive and Affective Intervention for Mild Cognitive Impairment (MCI) (CoINTEGRATE- for Foreign-Born Arab Americans- a Dyadic Approach)
The purpose of this pilot study is to evaluate the feasibility of a cognitive and affective intervention for foreign born Arab American dyads consisting of the person with Mild Cognitive Impairment (MCI) and participants caregiver. This study will evaluate the feasibility of a cognitive and affective intervention combining Cognitive Behavioral Therapy (CBT), Cognitive Rehabilitation Therapy (CRT), and modifiable lifestyle factors to address the cognitive and affective dysfunctions associated with Mild Cognitive Impairment (MCI) or those with cognitive complaints.
The study team hypothesizes that combining evidence-based cognitive and affective therapies (CRT+CBT) with lifestyle modifications is feasible and will improve the cognitive performance and Quality of Life (QoL) in patients with MCI and participants caregivers compared to usual care.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria for Persons with MCI:
- All patients diagnosed with MCI or Persons with Montreal Cognitive Assessment (MoCA) less or equal to 25
- Disease duration less or equal to 3 years
- Age older than 60 years
- Foreign-Born Arab origins, Language: Arabic or English
- Cognitive impairment ≥ 1.0 standard deviation below the test score normed for age and education in at least 2 cognitive domains (verbal learning and memory, processing speed, or visuospatial memory)
- Participants who can provide consent or legally authorized representative who can provide consent on their behalf
Inclusion Criteria for Caretakers:
- Identified by the patients as the person that provides the most care for them with regards to medical care; may be a spouse, an adult child, a sibling, a relative, or family friend
- Above the age of 18 years Fluent in Arabic and/or English
- Can complete a self-report questionnaire by interview or self-report.
Exclusion Criteria Persons with MCI:
- History of traumatic brain injury (TBI)
- Diagnosed with Covid-19
- Patients with other neurosensory or neurodegenerative diseases
- Younger than 60 years
- Psychiatric disorders other than mild to moderate anxiety and depression
- Diagnosed sleep disorders
- Visual or auditory impairment
- Current or history of alcohol or substance abuse/dependence
- Patients with severe depression or suicidal (ideation or plan) will be instructed to seek mental health, provided with resources, and referred to their primary care provider
Exclusion Criteria for Caretakers:
- Paid caregivers
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: CRT plus CBT and Lifestyle modifications
|
Participants will complete an 8-week intervention, 2 sessions per week.
Co-INTEGRATE sessions take 30-50 minutes to complete.
Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
Participants will complete an 8-week intervention, 2 sessions per week.
Co-INTEGRATE sessions take 30-50 minutes to complete.
Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
The therapy sessions are coupled with homework and requires some lifestyle modifications for the persons with MCI, such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.
|
|
Active Comparator: Usual care Psychoeducation
|
Participants will receive 15-minute psychoeducation session twice per week for 8 weeks. All research-related sessions will be web-based (on Zoom) and recorded (with approval). Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients that complete the study
Time Frame: week 8 (end of treatment)
|
week 8 (end of treatment)
|
|
|
Average number of sessions completed
Time Frame: week 8 (end of treatment)
|
week 8 (end of treatment)
|
|
|
Overall experience based qualitative semi-structured interview
Time Frame: Week 9 (after treatment ended)
|
This interview will be conducted at the end of the study and in the order of exit of participants to gather feedback about their satisfaction with the study.
This brief interview consists of 3 questions that ask the participants to describe the aspects of the intervention participants found beneficial, willingness to participate again, and whether it was appropriate for participants needs.
In addition, a brief quantitative satisfaction survey to rate overall satisfaction, how likely it would be recommend to others, and how satisfied participants are with telemedicine as a mode of delivery.
|
Week 9 (after treatment ended)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Short Form Health Survey (SF-36)
Time Frame: Week 9 (after treatment ended)
|
The SF-36 explores people's physical and mental health.
It consists of 36 items that assess role limitations due to personal or emotional problems, emotional well-being, social functioning, general health perceptions, perceived change in health.
Scores ranged from 0 (worst health status) to 100 (best health status).
|
Week 9 (after treatment ended)
|
|
Brief Visuospatial Memory test (BVMT-R-25 minutes)
Time Frame: Week 9 (after treatment ended)
|
This test is comprised of three memory trials (10 seconds each) followed by delayed recall after 25 minutes and a recognition trial. It has been widely used as a quick measure of visuospatial memory. The digital stimulus forms will be used (alternate form will be used at the end of the study to control for practice effect). Recall performance will record for each of the immediate recall trials (Trial 1, Trial 2, and Trial 3) and for the delayed recall trial (Delayed Recall). The study team will combine the recall scores to form three additional summary measures of learning and memory. Recognition Hits and False Alarms will be recorded during the delayed recognition task. Recognition Hits are calculated as the number of correct responses to target items, and Recognition False Alarms are calculated as the number of incorrect responses to nontarget items. Each trial is worth 0-12 points, so the total score is 0-36, a higher score indicates a better memory. |
Week 9 (after treatment ended)
|
|
California Verbal Learning Test-Third Edition (CVLT-3-60 minutes)
Time Frame: Week 9 (after treatment ended)
|
The California Verbal Learning Test, Third Edition (CVLT-3) measures both recall and recognition of two lists of words (List A and List B) over a number of immediate and delayed memory trials.
It provides an assessment of verbal learning and memory deficits in adults ages 16 - 90.
Score of 0-16, where a lower score indicates worse memory, and a high score indicates better memory.
|
Week 9 (after treatment ended)
|
|
The Symbol Digit Modalities Test Score (SDMT-5 minutes)
Time Frame: Week 9 (after treatment ended)
|
The Symbol Digit Modalities Test (SDMT) is used to assess divided attention, visual scanning, tracking and motor speed.
Using a reference key, the examinee has 90 seconds to pair specific numbers with given geometric figures.
Because examinees can give either written or spoken responses, the test is well suited for use with individuals who have motor disabilities or speech disorders.
Because it involves only geometric figures and numbers, the SDMT is relatively culture free as well and can be administered to individuals who do not speak English.
It takes approximately 5 minutes to complete the entire test.
Scoring involves summing the number of correct substitutions within the 90 second interval the max score is 110, where a higher score indicates a better memory
|
Week 9 (after treatment ended)
|
|
The Memory Complaint Scale (MCS-2 minute) score
Time Frame: Week 9 (after treatment ended)
|
The Memory Complaint Scale (MCS-2 min) is comprised of 14 items and is designed for subjective memory complaints.The test yields a total score with a classification in terms of memory complaint (MC) based on their score as follows: No MC (0-2), mild MC (3-6), moderate MC (7-10) or severe MC (11-14)
|
Week 9 (after treatment ended)
|
|
Arabic Verbal Memory Test (VMAT)
Time Frame: Week 9 (after treatment ended)
|
The Arabic Verbal Memory Test is a verbal memory test that consists of 3 lists (List A, List B (each 15 words), and a Recognition List (45 words).
It assesses verbal learning and memory in adults aged 16-90.
The scores will include scores on learning trials 1-5, free and cued short recall, interference trial free recall and delayed free and cued recall, yes/ no recognition, and forced choice recognition.
The test yields a score of 0-15, where a lower score indicates worse memory and a high score indicates better memory.
|
Week 9 (after treatment ended)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hala Darwish, PhD, University of Michigan
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HUM00227630
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Cognitive Impairment
-
Saglik Bilimleri UniversitesiAnkara UniversityRecruitingAmnestic Mild Cognitive Impairment | Amnestic Mild Cognitive DisorderTurkey
-
Masaryk UniversityRecruitingMild Cognitive Impairment (MCI) Amnestic | Lewy Body Disease With Mild Cognitive Impairment | Parkinson's Disease With Mild Cognitive ImpairmentCzechia
-
BaycrestCentre for Aging and Brain Health InnovationUnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive ImpairmentCanada
-
Singapore General HospitalSingapore Health ServicesNot yet recruitingMild Cognitive Impairment (MCI) | Mild Cognitive Impairment
-
Xuanwu Hospital, BeijingNot yet recruitingMild Cognitive Impairment (MCI)China
-
The Hong Kong Polytechnic UniversityJohns Hopkins University; The University of Hong Kong; University of ReadingNot yet recruitingMild Cognitive Impairment (MCI)Hong Kong
-
Universidad Complutense de MadridAB Biotics, SANot yet recruitingMild Cognitive Impairment (MCI)Spain
-
University of SheffieldNot yet recruitingMild Cognitive Impairment (MCI)United Kingdom
-
The Hong Kong Polytechnic UniversityRecruitingMild Cognitive Impairment (MCI)Hong Kong
-
Mackay Memorial HospitalBened Biomedical Co., Ltd.TerminatedMild Cognitive Impairment (MCI)Taiwan
Clinical Trials on CRT
-
Medtronic Cardiac Rhythm and Heart FailureMedtronicCompleted
-
Children's Hospital of PhiladelphiaThe Hilda & Preston Davis FoundationCompleted
-
Inova Health Care ServicesMedtronicActive, not recruitingLeft Bundle-Branch Block | Heart Failure (HF) | Left Ventricular Ejection FractionUnited States
-
Guy's and St Thomas' NHS Foundation TrustKing's College LondonNot yet recruiting
-
University Hospital OlomoucNot yet recruiting
-
Universidad Complutense de MadridCompleted
-
CMC Ambroise ParéWithdrawnCompare Two Programming Modalities for CRT Devices in Heart Failure Patients With an Indication for Cardiac Resynchronization TherapyMonaco, France
-
Medtronic Cardiac Rhythm and Heart FailureCompletedHeart Diseases | Atrioventricular BlockUnited States, Canada
-
Montreal Heart InstituteCanadian Institutes of Health Research (CIHR); Abbott Medical DevicesTerminated
-
Medtronic Cardiac Rhythm and Heart FailureTerminatedCongestive Heart Failure | Systolic Heart Failure | Left Bundle Branch BlockUnited States, Sweden, India, Russian Federation, United Kingdom